NASDAQ:BCYC

Bicycle Therapeutics - BCYC Stock Forecast, Price & News

$32.13

+1.01 (+3.25%)

(As of 12/8/2022 01:58 PM ET)

Add

Compare

Today's Range: $30.25
▼
$32.47
50-Day Range: $20.37
▼
$32.90
52-Week Range: $12.08
▼
$61.50

Volume: 9,029 shs
Average Volume: 248,036 shs
Market Capitalization: $953.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $52.40

Bicycle Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 66.8% Upside
$52.40 Price Target
Short Interest: Bearish
8.59% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.58
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.82) to ($4.36) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

770th out of 1,027 stocks

Pharmaceutical Preparations Industry

376th out of 503 stocks

3.4

Analyst's Opinion

Consensus Rating
Bicycle Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $52.40, Bicycle Therapeutics has a forecasted upside of 66.8% from its current price of $31.41.
Amount of Analyst Coverage
Bicycle Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.59% of the outstanding shares of Bicycle Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Bicycle Therapeutics has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Bicycle Therapeutics has recently decreased by 8.60%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Bicycle Therapeutics does not currently pay a dividend.
Dividend Growth
Bicycle Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BCYC.

3.1

News and Social Media Coverage

News Sentiment
Bicycle Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Bicycle Therapeutics this week, compared to 3 articles on an average week.
Search Interest
2 people have searched for BCYC on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bicycle Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.00% of the stock of Bicycle Therapeutics is held by insiders.
Percentage Held by Institutions
76.45% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($3.82) to ($4.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bicycle Therapeutics is -9.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bicycle Therapeutics is -9.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bicycle Therapeutics has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bicycle Therapeutics (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Stock News Headlines

December 7, 2022 | marketwatch.com

Bicycle Suspension Market New Innovations and Future Expansion 2022-2028

December 7, 2022 | marketwatch.com

Bicycle Hubs Market Share and Growth Drivers 2023: Qualitative Research by Developing Strategies, Global Size and Trends Forecast to 2029

December 6, 2022 | americanbankingnews.com

Bicycle Therapeutics plc (NASDAQ:BCYC) Short Interest Down 8.6% in November

December 5, 2022 | marketwatch.com

Bicycle Saddle Market 2023-2026 Find Out Essential Strategies To Expand The Business And Top Key Players

November 27, 2022 | msn.com

Monroe restaurant hosts 5th Annual Holiday Bicycle Drive

November 26, 2022 | marketwatch.com

Bicycle Tyres (Bike Tires) Market Share-Size Estimate 2023 with Top Leading Players & Future Demand, Emerging Trends till 2028

November 25, 2022 | marketwatch.com

Two-Wheel Bicycle Trailer Market 2022 : Production Capacity, Restring Drivers, Size and Landscape Outlook 2028

November 24, 2022 | marketwatch.com

Bicycle Racks Market 2022 Industry Size, Growth, Segments, Revenue, Manufacturers and 2028 Forecast Top Countries Data

November 23, 2022 | marketwatch.com

Bicycle Racks for Cars Market : Revenue, Growth Rate, Market Size, Restraints and Forecast Analysis by 2028

November 23, 2022 | marketwatch.com

Bicycle Gearbox Market Size 2023 Competitive Landscape, Regional Development, Major Manufacturers, Emerging Trends, Growth Opportunities to 2028

November 22, 2022 | marketwatch.com

Bicycle Market 2023 comprehensive report by global industry trends demand growth analysis share revenue and forecast 2028| Newest 126 Pages Report

November 22, 2022 | msn.com

'A lot of work to be done': Bicycle Man struggling to find volunteers for final giveaway

November 10, 2022 | finance.yahoo.com

Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting

November 9, 2022 | finance.yahoo.com

Bicycle Therapeutics Third Quarter 2022 Earnings: Misses Expectations

November 8, 2022 | finance.yahoo.com

What You Need To Know About The Bicycle Therapeutics plc (NASDAQ:BCYC) Analyst Downgrade Today

November 8, 2022 | finance.yahoo.com

Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update

November 7, 2022 | marketwatch.com

Bicycle Shifters Market Share 2023 Growth Factor, Industry Challenge, Business Overview, Size and Forecast to 2029

November 4, 2022 | marketwatch.com

Electric Assist Bicycle Market 2022 : Report Offers Key Futuristic Top Trends And Competitive Landscape By 2028

November 4, 2022 | marketwatch.com

LED Bicycle Lights Market Research 2022 | Emerging Growth Factors, Key Dynamics, Sales Channel, Trends, Top Manufacturers and Size Forecast to 2028

November 3, 2022 | benzinga.com

Insights on the Bicycle Global Market to 2027 - Electric Segment Shows Promising Growth

November 3, 2022 | marketwatch.com

Folding Electric Bicycle Market Size, Share, Global Growth Analysis, Trends, Industry Analysis, Key Players and Forecast to 2028

November 3, 2022 | benzinga.com

Recap: Bicycle Therapeutics Q3 Earnings

November 3, 2022 | finance.yahoo.com

Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 2, 2022 | marketwatch.com

Bicycle Rear Derailleurs Market Size with SWOT Analysis is Likely to Accelerate Industry Growth in Consumer Goods

November 1, 2022 | marketwatch.com

Bicycle Stems Market Report : Global Size, Share, Growth and Industry Trends 2022 To 2028 | 120 Report Pages

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Company Calendar

Last Earnings: 11/03/2021
Today: 12/08/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/07/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BCYC
CUSIP: N/A
CIK: 1761612
Web: www.bicycletherapeutics.com
Phone: 441223261503
Fax: N/A
Employees: 119
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $52.40
High Stock Price Forecast: $80.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +63.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.42)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-66,820,000.00
Net Margins: -669.65%
Pretax Margin: -681.96%
Return on Equity: -31.56%
Return on Assets: -22.37%

Debt

Debt-to-Equity Ratio: 0.10
Current Ratio: 9.18
Quick Ratio: 9.18

Sales & Book Value

Annual Sales: $11.70 million
Price / Sales: 81.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.78 per share
Price / Book: 2.73

Miscellaneous

Outstanding Shares: 29,690,000
Free Float: 27,017,000
Market Cap: $953.94 million
Optionable: Not Optionable
Beta: 0.79

Key Executives

Dr. Kevin Lee M.B.A. (Age 53)
Ph.D., CEO & Exec. Director
Comp: $1.4M

Mr. Lee H. Kalowski M.B.A. (Age 41)
MBA, Pres & CFO
Comp: $832.36k

Sir Gregory Paul Winter CBE (Age 71)
FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board
Comp: $40k

Dr. Michael Skynner B.sc. Ph.d. (Age 52)
Ph.D., Chief Technology Officer
Comp: $925.3k

Dr. Christian Heinis
Scientific Founder

Mr. Alistair Milnes
Chief Operating Officer

Dr. Nicholas Keen Ph.D. (Age 54)
Chief Scientific Officer

Mr. David E. Borah CFA
VP of Capital Markets & Investor Relations

Mr. Zafar Qadir
Gen. Counsel

Dr. Gillian Langford
Head of Clinical and Project Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCYC Stock - Frequently Asked Questions

Should I buy or sell Bicycle Therapeutics stock right now?: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCYC shares.
View BCYC analyst ratings or view top-rated stocks.
What is Bicycle Therapeutics' stock price forecast for 2023?: 12 Wall Street research analysts have issued 12 month price objectives for Bicycle Therapeutics' shares. Their BCYC share price forecasts range from $30.00 to $80.00. On average, they anticipate the company's stock price to reach $52.40 in the next year. This suggests a possible upside of 70.1% from the stock's current price.
View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts.
How have BCYC shares performed in 2022?: Bicycle Therapeutics' stock was trading at $60.87 at the start of the year. Since then, BCYC stock has decreased by 49.4% and is now trading at $30.81.
View the best growth stocks for 2022 here.
Are investors shorting Bicycle Therapeutics?: Bicycle Therapeutics saw a decrease in short interest in November. As of November 15th, there was short interest totaling 2,550,000 shares, a decrease of 8.6% from the October 31st total of 2,790,000 shares. Based on an average daily volume of 218,700 shares, the days-to-cover ratio is presently 11.7 days.
View Bicycle Therapeutics' Short Interest.
When is Bicycle Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our BCYC earnings forecast.
How were Bicycle Therapeutics' earnings last quarter?: Bicycle Therapeutics plc (NASDAQ:BCYC) announced its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.02. The firm earned $4.33 million during the quarter, compared to analyst estimates of $5.29 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 31.56% and a negative net margin of 669.65%.

What other stocks do shareholders of Bicycle Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC).
When did Bicycle Therapeutics IPO?: (BCYC) raised $64 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.
What is Bicycle Therapeutics' stock symbol?: Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."
Who are Bicycle Therapeutics' major shareholders?: Bicycle Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Logos Global Management LP (6.74%), Samlyn Capital LLC (4.36%), Point72 Asset Management L.P. (4.23%), Tybourne Capital Management HK Ltd. (3.51%), First Light Asset Management LLC (2.37%) and Price T Rowe Associates Inc. MD (1.41%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends.
How do I buy shares of Bicycle Therapeutics?: Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Bicycle Therapeutics' stock price today?: One share of BCYC stock can currently be purchased for approximately $30.81.
How much money does Bicycle Therapeutics make?: Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $914.75 million and generates $11.70 million in revenue each year. The company earns $-66,820,000.00 in net income (profit) each year or ($3.42) on an earnings per share basis.
How many employees does Bicycle Therapeutics have?: The company employs 119 workers across the globe.
How can I contact Bicycle Therapeutics?: Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503.

This page (NASDAQ:BCYC) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial